Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) - Equities researchers at Wedbush decreased their FY2029 earnings per share estimates for shares of Black Diamond Therapeutics in a report released on Thursday, August 7th. Wedbush analyst R. Driscoll now expects that the company will earn $0.37 per share for the year, down from their previous forecast of $0.39. The consensus estimate for Black Diamond Therapeutics' current full-year earnings is ($1.30) per share.
Black Diamond Therapeutics (NASDAQ:BDTX - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.06.
Several other research analysts also recently commented on the company. Raymond James Financial raised Black Diamond Therapeutics to an "outperform" rating and set a $11.00 price objective for the company in a research note on Tuesday, July 1st. Wall Street Zen downgraded Black Diamond Therapeutics from a "buy" rating to a "hold" rating in a research note on Saturday. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $12.80.
Read Our Latest Analysis on Black Diamond Therapeutics
Black Diamond Therapeutics Stock Performance
NASDAQ BDTX opened at $2.40 on Monday. The business has a fifty day moving average price of $2.64 and a 200 day moving average price of $2.14. Black Diamond Therapeutics has a one year low of $1.20 and a one year high of $6.75. The company has a market cap of $136.66 million, a P/E ratio of 10.44 and a beta of 2.87.
Institutional Trading of Black Diamond Therapeutics
Several large investors have recently added to or reduced their stakes in BDTX. Raymond James Financial Inc. purchased a new stake in Black Diamond Therapeutics in the 4th quarter valued at $53,000. Sei Investments Co. purchased a new stake in Black Diamond Therapeutics in the 4th quarter valued at $49,000. JPMorgan Chase & Co. grew its holdings in Black Diamond Therapeutics by 429.6% in the 4th quarter. JPMorgan Chase & Co. now owns 18,929 shares of the company's stock valued at $41,000 after buying an additional 15,355 shares in the last quarter. Wellington Management Group LLP grew its holdings in Black Diamond Therapeutics by 7.9% in the 4th quarter. Wellington Management Group LLP now owns 221,236 shares of the company's stock valued at $473,000 after buying an additional 16,279 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in Black Diamond Therapeutics by 1.5% in the 4th quarter. Geode Capital Management LLC now owns 959,316 shares of the company's stock valued at $2,053,000 after buying an additional 14,439 shares in the last quarter. 95.47% of the stock is currently owned by hedge funds and other institutional investors.
Black Diamond Therapeutics Company Profile
(
Get Free Report)
Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Black Diamond Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Black Diamond Therapeutics wasn't on the list.
While Black Diamond Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.